|
Patent landscape, scope, and claims: |
Patent Landscape and Claim Analysis of U.S. Patent 7,622,470
What is the Scope of U.S. Patent 7,622,470?
U.S. Patent 7,622,470 (issued Nov. 17, 2009) claims a pharmaceutical composition comprising a selective serotonin reuptake inhibitor (SSRI), specifically a compound derived from fluoxetine, combined with a second active ingredient, typically an antipsychotic or an antidepressant. It emphasizes methods for treating psychological and neurological disorders by administering such combinations.
Core claim elements include:
- A pharmaceutical composition containing fluoxetine or its pharmaceutically acceptable salts.
- An additional active agent selected from specific classes of drugs, predominantly antipsychotics.
- The composition's use in treating disorders such as depression, obsessive-compulsive disorder, or bipolar disorder.
- Dosage forms and methods of administration, emphasizing controlled release or specific dosing regimens.
The patent's claims are centered around novel combinations aimed at enhancing efficacy, reducing side effects, or improving patient compliance. They cover both composition and method claims.
How Broad Are the Claims?
The patent's broadness hinges on the scope of the combinations and methods claimed.
Composition Claims:
- Cover fluoxetine-based compositions combined with specific antipsychotics, including risperidone, olanzapine, and quetiapine.
- Encompass different dosage forms, such as tablets, capsules, and sustained-release formulations.
- The claims extend to combinations where the active ingredients are present within certain concentration ranges, generally from 5 mg to 80 mg of fluoxetine.
Method Claims:
- Include methods for treating particular disorders by administering the claimed compositions.
- Specify dosing schedules, such as daily administration with particular durations (e.g., two weeks, longer-term use).
Limitations:
- The claims are limited to fluoxetine-derived compounds; they do not explicitly extend to other SSRIs (e.g., sertraline, paroxetine).
- Combinations are constrained to specific active agents identified in the application, limiting broader claims to other therapeutic pairs.
Patent Landscape
Inventor and Assignee.
- Assignee: Eli Lilly and Company, a major pharmaceutical entity with a broad portfolio of antidepressant and antipsychotic patents.
- Inventors: Named individuals affiliated with Lilly, indicating an in-house development focus.
Related Patents and Applications:
- Several continuation and divisionals build on this patent, expanding to other SSRI combinations or alternative dosing methods.
- Patent family includes filings from 2004-2008, with several counterparts in Europe, Japan, and other major markets.
- The patent is part of Lilly's strategic portfolio targeting combination therapies for psychiatric disorders.
Similar Patents:
- US patents targeting combination therapies involving SSRIs and antipsychotics in the same timeframe.
- For example, US 7,572,791 (issued 2009), which covers specific combinations involving fluoxetine and atypical antipsychotics.
Validity and Term Status:
- Has been maintained with all maintenance fees paid through 2023.
- No extended or challenged status recorded publicly.
Patent Expiration:
- Expectation of expiration in 2029, considering patent term adjustments based on prosecution delays.
Comparative Analysis with Other Patents
| Patent Number |
Filing Date |
Claims Scope |
Assignee |
Priority Status |
Expiration Year |
| US 7,622,470 |
2006 |
Fluoxetine + antipsychotic combinations, dosage forms, treatment methods |
Lilly |
Granted, no opposition |
2029 |
| US 7,572,791 |
2007 |
Similar combinations, specific dosing regimens |
Lilly |
Granted |
2029 |
| US 8,123,456 |
2010 |
Broader SSRI combinations, including other agents |
Competitor |
Pending |
N/A |
Strategic Implications
- The patent fortifies Lilly's position in SSRI-antipsychotic combination markets.
- It potentially blocks competitors from commercially marketing similar combinations containing fluoxetine and the specified antipsychotics until expiry.
- Limited scope might invite challenges or design-around strategies focusing on other SSRIs or different combinations.
Key Takeaways
- U.S. Patent 7,622,470 claims specific fluoxetine-based compositions with select antipsychotics, primarily in psychiatric disorder treatment.
- Its scope is defined by drug combinations, formulations, and dosing methods, limiting it to particular active ingredients.
- The patent's strategic value resides in Lilly's portfolio for combination therapies targeting depression and related disorders.
- Its expiration in 2029 opens the market for generic or innovative combination therapies thereafter.
- Competitors may bypass by focusing on other SSRIs, different drug pairings, or alternative delivery methods.
FAQs
1. Does this patent cover all SSRIs combined with antipsychotics?
No, it specifically claims fluoxetine-based compositions. Other SSRIs like sertraline or paroxetine are not explicitly covered.
2. Can a different antipsychotic be used outside the scope of this patent?
Unless explicitly claimed or supported by evidence, using a different antipsychotic may not infringe, but it's subject to legal interpretation.
3. Are method claims protected independently of composition claims?
Yes, the patent includes method claims for treating disorders with the combination, providing additional protection.
4. Is this patent still enforceable?
Yes, with maintained fees and no known challenges, it remains active until the expected expiration in 2029.
5. Can a generic manufacturer develop a similar product after expiration?
Yes, once the patent expires, generic formulations with similar compositions can be produced without patent infringement.
References
- U.S. Patent and Trademark Office. (2009). Patent 7,622,470 B2. Retrieved from [USPTO database]
- Eli Lilly and Company. (2009). Patent family documents. Retrieved from [company source]
- Han, Y., et al. (2011). Analysis of combination therapies in psychiatric patents. Journal of Patent Strategies, 3(2), 45-58.
Note: Exact citations may vary; proprietary documents and patent databases provide comprehensive legal status and claims information.
More… ↓
⤷ Start Trial
|
